[Medical treatment of small cell lung cancer: Can we leave the area of cisplatin-etoposide?]
| Autor: | Pujol, Jean-Louis, Roch, Benoit, Pujol, Camille, Goze, Catherine |
|---|---|
| Přispěvatelé: | Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM), CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Université de Montpellier (UM), Institut de Génomique Fonctionnelle (IGF), Université de Montpellier (UM)-Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Montpellier 2 - Sciences et Techniques (UM2)-Centre National de la Recherche Scientifique (CNRS), Institut des Neurosciences de Montpellier - Déficits sensoriels et moteurs (INM), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM) |
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
Benzodiazepinones
Immunoconjugates Lung Neoplasms DNA Repair Receptors Notch Tumor Suppressor Proteins [SDV]Life Sciences [q-bio] Antineoplastic Agents Poly(ADP-ribose) Polymerase Inhibitors Protein Serine-Threonine Kinases Antibodies Monoclonal Humanized Small Cell Lung Carcinoma Dacarbazine DNA Repair Enzymes Temozolomide Humans Enhancer of Zeste Homolog 2 Protein DNA Modification Methylases Aurora Kinase A DNA Damage |
| Zdroj: | Bulletin du Cancer Bulletin du Cancer, John Libbey Eurotext, 2018, 105 (10), pp.955-966. ⟨10.1016/j.bulcan.2018.05.014⟩ |
| ISSN: | 0007-4551 1769-6917 |
| DOI: | 10.1016/j.bulcan.2018.05.014⟩ |
| Popis: | Small cell lung cancer accounts for 14% of all lung cancers. It remains a major challenge for oncology as the progresses made in the past three decades are modest. After a rapid overview of current knowledge regarding somatic genomic alterations, this state-of-art addresses pathways to improve small-cell lung cancer outcome such as the targeting of DNA damage repair mechanisms firstly anti-PARPs, inhibitory molecules of EZH2, derepression of the NOTCH pathway, rovalbituzumab-tesirine, inhibition of serine/threonine Aurora A kinase, temozolomide and its dependence on methylation of the MGMT promoter. This first chapter suggests the beginning of precision medicine in small cell lung cancer. The last section focuses on the development of immuno-oncological agents and the information collected from phase 1 and 2 studies: the low intensity of PD-L1 tissue expression and the possible relationship of the activity of these agents as a function of tumor mutational burden are pointed out. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|